Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Additional Reading from MarketBeat
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Authored by Jeffrey Neal Johnson. Originally Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk already made me a “wealthy man”
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
Abbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 in the last trading days of March. This sharp downturn has many wondering whether the foundation of this industry leader is cracking. A closer look at Abbott Laboratories’s current position suggests a gap between market sentiment and operational reality, raising an important question: Is the market’s pessimism justified, or has a compelling long-term value opportunity emerged? Separating the Signal From the NoiseAbbott's recent decline reflects two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, primarily due to market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has acknowledged the challenge and outlined a clear turnaround plan. CEO Robert B. Ford described pricing and promotion initiatives and a pipeline of at least eight new product launches in 2026, with a forecasted return to growth in the second half of the year. The second factor is external and broader in scope: a rotation of capital across the market. In periods of economic optimism, investors often move funds away from stable, defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector in pursuit of faster returns. That broader trend has weighed on many fundamentally sound healthcare companies, including Abbott, pressuring their share prices for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile the Nutrition segment works toward a short-term recovery, Abbott's core businesses remain robust, led by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model provides a powerful counterbalance to isolated weakness in Nutrition, and the company’s strongest growth drivers are firing on multiple cylinders.
Medical Devices: The Medical Devices business is ramping up, driven by market-leading innovation across critical-care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) continues to be a major growth engine. This line, which lets users track glucose levels without routine fingersticks, generated more than $7.5 billion in sales in 2025 and remains central to Abbott's long-term growth. Cardiovascular Leadership: Abbott is also a dominant force in cardiovascular health. Its Electrophysiology business grew at a double-digit rate, and the Structural Heart business posted strong organic growth of 8.7%. That strength is supported by best-in-class products such as MitraClip and TriClip, which offer minimally invasive solutions for heart valve repair. Abbott also has a pipeline of innovations, including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also making a major strategic move to secure future growth through the acquisition of Exact Sciences. Exact Sciences is a leader in cancer screening and diagnostics, best known for its non-invasive colon cancer test, Cologuard. The deal will position Abbott as a leader in the rapidly expanding market for cancer diagnostics, adding a new, high-growth vertical that could be a significant revenue contributor for years to come. This bullish outlook is not just company rhetoric; it is shared by analysts. Wall Street maintains a Moderate Buy consensus rating on the stock. The average 12-month price target is $135.47, implying potential upside of more than 30% from current levels and suggesting many analysts view the shares as undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on income, Abbott’s dividend is a standout feature. Abbott Laboratories is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record underscores a strong commitment to returning capital to shareholders through all market cycles. The recent decline in Abbott’s stock price has a practical benefit for new investors: a higher dividend yield. At current prices, Abbott offers a dividend yield of about 2.5%, allowing investors to lock in a higher rate of income from a historically reliable payer. The dividend also looks secure: Abbott's dividend payout ratio is roughly 68% of earnings. More importantly, the dividend represents only about 37% of the company's operating cash flow, indicating Abbott generates ample cash to cover payments and support future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott appears disconnected from the company's business reality. Temporary headwinds in a single division and broader market rotations have depressed the stock price, even as Abbott's fundamental growth engines accelerate. Its dominant Medical Devices division continues to deliver robust results, the dividend remains a dependable income foundation, and catalysts like the Exact Sciences acquisition could drive substantial long-term growth. For investors with a multi-year horizon, the disparity between price and fundamental value presents an opportunity worth considering. |
